Clinical Trial Update: EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating EZ-2053 for prophylaxis of acute pulmonary allograft rejection; the study is completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchiectasis
• Chronic Obstructive Pulmonary Disease
• Cystic Fibrosis
• Idiopathic Pulmonary Fibrosis
• Pulmonary Vascular Disease

Drugs mentioned

• EZ-2053

Snippet

Sponsor: Neovii Biotech | Conditions: Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2012-06-08